192 related articles for article (PubMed ID: 19909255)
21. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
Tan B; Jiang DJ; Huang H; Jia SJ; Jiang JL; Hu CP; Li YJ
Vascul Pharmacol; 2007 May; 46(5):338-45. PubMed ID: 17293168
[TBL] [Abstract][Full Text] [Related]
22. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
[TBL] [Abstract][Full Text] [Related]
23. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells.
Sakurada M; Shichiri M; Imamura M; Azuma H; Hirata Y
Hypertension; 2008 Nov; 52(5):903-9. PubMed ID: 18824664
[TBL] [Abstract][Full Text] [Related]
24. Homocysteine increases the production of asymmetric dimethylarginine in cultured neurons.
Selley ML
J Neurosci Res; 2004 Jul; 77(1):90-3. PubMed ID: 15197741
[TBL] [Abstract][Full Text] [Related]
25. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Desai A; Zhao Y; Warren JS
Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
[TBL] [Abstract][Full Text] [Related]
26. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
27. Dimethylarginine dimethylaminohydrolase 1 modulates endothelial cell growth through nitric oxide and Akt.
Zhang P; Hu X; Xu X; Chen Y; Bache RJ
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):890-7. PubMed ID: 21212404
[TBL] [Abstract][Full Text] [Related]
28. Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury.
Stühlinger MC; Conci E; Haubner BJ; Stocker EM; Schwaighofer J; Cooke JP; Tsao PS; Pachinger O; Metzler B
Cardiovasc Res; 2007 Jul; 75(2):417-25. PubMed ID: 17559823
[TBL] [Abstract][Full Text] [Related]
29. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury.
Konishi H; Sydow K; Cooke JP
J Am Coll Cardiol; 2007 Mar; 49(10):1099-105. PubMed ID: 17349891
[TBL] [Abstract][Full Text] [Related]
30. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.
Jia SJ; Jiang DJ; Hu CP; Zhang XH; Deng HW; Li YJ
Vascul Pharmacol; 2006 Mar; 44(3):143-8. PubMed ID: 16309971
[TBL] [Abstract][Full Text] [Related]
31. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications.
Yamagishi S; Ueda S; Nakamura K; Matsui T; Okuda S
Curr Pharm Des; 2008; 14(25):2613-8. PubMed ID: 18991678
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effect of resveratrol derivative BTM-0512 on high glucose-induced cell senescence involves dimethylaminohydrolase/asymmetric dimethylarginine pathway.
Yuan Q; Peng J; Liu SY; Wang CJ; Xiang DX; Xiong XM; Hu CP; Li YJ
Clin Exp Pharmacol Physiol; 2010 May; 37(5-6):630-5. PubMed ID: 20132235
[TBL] [Abstract][Full Text] [Related]
33. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence.
Scalera F; Borlak J; Beckmann B; Martens-Lobenhoffer J; Thum T; Täger M; Bode-Böger SM
Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1816-22. PubMed ID: 15308550
[TBL] [Abstract][Full Text] [Related]
34. PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy.
Chen Y; Xu X; Sheng M; Zhang X; Gu Q; Zheng Z
Exp Eye Res; 2009 Dec; 89(6):1028-34. PubMed ID: 19748504
[TBL] [Abstract][Full Text] [Related]
35. ADMA regulates angiogenesis: genetic and metabolic evidence.
Achan V; Ho HK; Heeschen C; Stuehlinger M; Jang JJ; Kimoto M; Vallance P; Cooke JP
Vasc Med; 2005 Feb; 10(1):7-14. PubMed ID: 15920994
[TBL] [Abstract][Full Text] [Related]
36. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
[TBL] [Abstract][Full Text] [Related]
37. Role of endogenous nitric oxide synthase inhibitor in gastric mucosal injury.
Wang L; Zhou Y; Peng J; Zhang Z; Jiang DJ; Li YJ
Can J Physiol Pharmacol; 2008 Mar; 86(3):97-104. PubMed ID: 18418436
[TBL] [Abstract][Full Text] [Related]
38. The DDAH/ADMA pathway is a critical regulator of NO signalling in vascular homeostasis.
Fiedler L
Cell Adh Migr; 2008; 2(3):149-50. PubMed ID: 19270535
[TBL] [Abstract][Full Text] [Related]
39. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases.
Pullamsetti SS; Savai R; Schaefer MB; Wilhelm J; Ghofrani HA; Weissmann N; Schudt C; Fleming I; Mayer K; Leiper J; Seeger W; Grimminger F; Schermuly RT
Circulation; 2011 Mar; 123(11):1194-204. PubMed ID: 21382892
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance of asymmetric dimethylarginine.
Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
